Acousia Completes Patient Enrollment for Cisplatin Ototoxicity Prevention Study
The Phase 2 PROHEAR trial is evaluating ACOU085 (Bimokalner) for its efficacy in protecting hearing during chemotherapy.
Tag: pharmaceuticals
All
Latest
All
Latest
Sensorion Announces Positive Data from Audiogene SENS-501 Clinical Trial
Sensorion’s Phase 1/2 Audiogene trial of the gene therapy SENS-501 for infants and toddlers with OTOF-related congenital deafness shows promising early safety and hearing improvement data, particularly in one patient, with a higher dose cohort now underway.
All
Latest
Sensorineural Hearing Loss Treatment Project Selected for Pilot Program
The Ear Science Institute Australia's project on sensorineural hearing loss treatment will receive research support from MedChem Australia.
Kathleen Campbell Updates ADA Attendees on Otoprotective Agents That Are Currently in or Approaching Clinical Trials
In the General Session of the 2014 Academy of Doctors of Audiology (ADA) Convention held November 6-9, 2014 in Las Vegas, Kathleen Campbell, PhD, of Southern Illinois University School of Medicine, gave an interesting and lively talk on ototoxicity and the role of pharmaceutical agents in hearing loss management and prevention.
Read MoreC&EN Publishes Article on Pharmaceutical Approaches to Hearing Treatment
More pharmaceutical and research companies are developing drugs to treat and prevent hearing loss, according to an April 7 article in Chemical & Engineering News (C&EN).
Read More